nerlynx for breast cancer

Release time ：Nov-17,2024

Nerlynx is a drug employed in the treatment of breast cancer, often utilized as a maintenance therapy following trastuzumab treatment for individuals with HER2-positive breast cancer. This medication may contribute to a reduced risk of cancer relapse.

Nerlynx operates by inhibiting the epidermal growth factor receptor (EGFR), thereby hindering the growth and dissemination of cancer cells. EGFR is a protein located on the surface of many cancer cell types and is integral to cellular growth and division processes. By targeting EGFR, Nerlynx can mitigate or halt the multiplication of cancer cells.

Patients using Nerlynx are advised to adhere to their physician's instructions and take the medication precisely as directed. Self-adjustment of dosage or cessation of medication is discouraged to prevent any impact on treatment effectiveness or the emergence of adverse effects. Additionally, it is essential for patients to undergo regular follow-ups during treatment to allow physicians to tailor the therapeutic approach based on the evolving condition.